Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence

Facing one of the biopharma industry’s steepest patent cliffs for the decade, Amgen has been on a shopping spree.

The latest purchase? A $3.7 billion deal to acquire ChemoCentryx.